.Attributes Medication, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of patients with HER2+ innovative bosom cancer cells and also energetic or secure mind metastases presented constant intracranial activity and also wide spread efficiency of T-DXd.